{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:21:51Z","timestamp":1707524511760},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,16]]},"DOI":"10.7759\/cureus.24177","type":"journal-article","created":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T10:52:10Z","timestamp":1650106330000},"source":"Crossref","is-referenced-by-count":0,"title":["Recurrence 14 Years After Initial Treatment of Extranodal NK\/T Cell Lymphoma, Nasal Type"],"prefix":"10.7759","author":[{"given":"Ryo","family":"Kawaura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe ES","year":"2017","unstructured":"Jaffe ES. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, et al. (ed): IARC, Lyon, France; 2017."},{"key":"ref2","unstructured":"extranodal NK\/T-cell lymphoma, nasal type. ENKL [Japanese]. (2018). Accessed: April 4, 2022: http:\/\/www.jshem.or.jp\/gui-hemali\/2_9.html#soron."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2169\/naika.97.1595","article-title":"Malignant lymphoma. Physiopathology and treatment: 4. NK\/T cell lymphoma [Japanese]","volume":"97","author":"Yamaguchi M","year":"2008","unstructured":"Yamaguchi M. Malignant lymphoma. Physiopathology and treatment: 4. NK\/T cell lymphoma [Japanese]. Nihon Naika Gakkai Zasshi. 2008, 97:1595-601. 10.2169\/naika.97.1595","journal-title":"Nihon Naika Gakkai Zasshi"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008265532487","article-title":"Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project","volume":"9","author":"Anderson JR","year":"1998","unstructured":"Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998, 9:717-20. 10.1023\/a:1008265532487","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.174.4.1741141","article-title":"Nasal T-cell\/natural killer cell lymphoma: CT and MR imaging features of a new clinicopathologic entity","volume":"174","author":"Ooi GC","year":"2000","unstructured":"Ooi GC, Chim CS, Liang R, Tsang KW, Kwong YL. Nasal T-cell\/natural killer cell lymphoma: CT and MR imaging features of a new clinicopathologic entity. AJR Am J Roentgenol. 2000, 174:1141-5. 10.2214\/ajr.174.4.1741141","journal-title":"AJR Am J Roentgenol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951201)76:11%3C2351::aid-cncr2820761125%3E3.0.co;2-1","article-title":"Frequent expression of P-glycoprotein\/MDR1 by nasal T-cell lymphoma cells","volume":"76","author":"Yamaguchi M","year":"1995","unstructured":"Yamaguchi M, Kita K, Miwa H, et al.. Frequent expression of P-glycoprotein\/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995, 76:2351-6. 10.1002\/1097-0142(19951201)76:11%3C2351::aid-cncr2820761125%3E3.0.co;2-1","journal-title":"Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.2.599","article-title":"P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833","volume":"93","author":"Egashira M","year":"1999","unstructured":"Egashira M, Kawamata N, Sugimoto K, et al.. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood. 1999, 93:599-606. 10.1182\/blood.V93.2.599","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.11477\/mf.1411202638","article-title":"Lymphoma and related diseases [Japanese]","volume":"93","author":"Yoshino T","year":"2021","unstructured":"Yoshino T. Lymphoma and related diseases [Japanese]. Jibi Inkoka, Tokeibu Geka. 2021, 93:250-5. 10.11477\/mf.1411202638","journal-title":"Jibi Inkoka, Tokeibu Geka"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4505","article-title":"Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK\/T cell lymphoma in the era of asparaginase","volume":"6","author":"Wang L","year":"2015","unstructured":"Wang L, Wang H, Wang JH, et al.. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK\/T cell lymphoma in the era of asparaginase. Oncotarget. 2015, 6:30317-26. 10.18632\/oncotarget.4505","journal-title":"Oncotarget"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi M","year":"2011","unstructured":"Yamaguchi M, Kwong YL, Kim WS, et al.. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011, 29:4410-6. 10.1200\/JCO.2011.35.6287","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/93380-recurrence-14-years-after-initial-treatment-of-extranodal-nkt-cell-lymphoma-nasal-type","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:01Z","timestamp":1707507961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/93380-recurrence-14-years-after-initial-treatment-of-extranodal-nkt-cell-lymphoma-nasal-type"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,16]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.24177","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,16]]}}}